Initial experience evaluating 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a phase I radioimmunotherapy trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples